Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR
J Infect Dis
; 182(4): [1199-206], Oct. 2000.
Article
em En
| ECUADOR
| ID: equ-6979
Biblioteca responsável:
EC107
Localização: Pubmed
ABSTRACT
Because concurrent infections with geohelminth parasites might impair the immune response to oral vaccines, we studied the vibriocidal antibody response to the oral cholera vaccine CVD 103-HgR in children infected with Ascaris lumbricoides and investigated the effect of albendazole pretreatment on the postvaccination response. Children with ascariasis were randomized to receive either 2 sequential doses of 400 mg of albendazole or placebo. After the second dose, CVD 103-HgR was given, and serum vibriocidal antibody levels were measured before and 10 days after vaccination. Postvaccination rates of seroconversion were greater in the treatment group that received albendazole (P=.06). Significantly greater rates of seroconversion and geometric mean titer were observed in the albendazole group in subjects with non-O ABO blood groups. A significant association was observed between vibriocidal seroconversion rates and treatment group, suggesting that A. lumbricoides infections impair the immune response to oral cholera vaccine, particularly in subjects of non-O blood groups.(AU)
Palavras-chave
Buscar no Google
Coleção BVS Equador:
Collection_ecuador
Base de dados:
ECUADOR
Assunto principal:
Ascaríase
/
Vacinas contra Cólera
/
Antiparasitários
Limite:
Humans
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2000
Tipo de documento:
Article